ASX / Media Release
24 October 2022

First UK Clinical Site Activated in IIH EVOLVE Phase III Clinical Trial

Invex Therapeutics Ltd (**Invex**, **ASX:IXC,** or **the Company**) a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (sustained release Exenatide) for neurological conditions relating to raised intracranial pressure, today announces the opening of the Company's first clinical site in the United Kingdom (UK) at University Hospital, Birmingham, which allows for patient screening and recruitment to commence in the UK for the Company's IIH EVOLVE Phase III clinical trial.

Professor Susan Mollan, consultant Neuro-Ophthalmologist at University Hospital Birmingham, Director of Ophthalmic Research at University Hospital Birmingham, Director of the Ocular Reading Centre and IIH EVOLVE Trial Steering Committee member commented "IIH EVOLVE is the first major Phase III clinical trial in IIH seeking regulatory approval for a new therapeutic agent, and if successful, would represent a major shift in the current IIH treatment paradigm. With the incidence rates of IIH in the UK accelerating and the economic cost of managing patients significant, I am pleased to be involved in this important clinical trial to assess the efficacy and safety of Presendin™ in IIH patients, where a first-line, standard drug therapy intervention is desperately needed."

Professor Alex Sinclair, Executive Director and Chief Scientific Officer of Invex said "Professor Mollan is considered one of the leading clinicians and researchers in the field of IIH globally, having authored a significant number of peer reviewed publications in the field and co-authored the current consensus treatment guidelines for IIH used by clinicians across the globe. We are therefore very pleased Professor Mollan has joined the IIH EVOLVE trial as an investigator and Steering Committee Member."

IIH EVOLVE is a randomised, placebo-controlled, double-blind trial that will randomise 240 patients with newly diagnosed IIH to determine the efficacy and safety of Presendin™ versus placebo, administered once weekly over 24 weeks. The primary endpoint of the trial is the change in intracranial pressure from baseline, with key secondary endpoints related to vision and headache outcome measures. Invex intends to open up to 40 clinical sites globally. Information on the trial is available at clinicaltrials.gov under Identifier **NCT05347147**.

- ENDS -

This release dated 24 October 2022 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.

For more information, please contact:

Company/Investors
Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media
Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter **@InvexThera_ASX**

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.

About Idiopathic Intracranial Hypertension (IIH)

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

About Presendin™

Presendin™ is a once per week, sub-cutaneous, sustained-release (SR) Exenatide microsphere formulation originally developed by Peptron, Inc. (KOSDAQ: 087010). In September 2021 Invex entered into an exclusive collaboration, manufacturing and supply agreement with Peptron for Presendin™ in IIH for all major markets, with the exception of South Korea.

Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which is currently approved for the treatment of type 2 diabetes. In 2017, Invex received orphan drug designation for Exenatide in IIH from the US Food and Drug Administration and European Medicines Agency.

About the IIH EVOLVE Clinical Trial

The Phase III IIH EVOLVE trial is a randomised, placebo-controlled, double-blind, multi-centre trial that will randomise 240 patients with newly diagnosed IIH to determine the efficacy and safety of Presendin™ versus placebo, administered once weekly. Patients with a confirmed diagnosis of IIH will be randomised on a 1:1 basis to either Presendin™ or placebo for 24 weeks.

The primary endpoint of the trial is the change in intracranial pressure (ICP), as measured by lumbar puncture, at baseline and at 24 weeks. Secondary endpoints include the change in perimetric mean deviation (PMD), papilloedema and monthly headache days over 24 weeks.

IIH EVOLVE is designed to meet the requirements for market approval of Presendin™ for the treatment of Idiopathic Intracranial Hypertension (IIH) in the European Union (EU), United Kingdom (UK) and Australia.

Further study details can be found at clinicaltrials.gov website under Identifier **NCT05347147** or by visiting: https://clinicaltrials.gov/ct2/show/NCT05347147.